Skip Navigation

Annals of Oncology 2004 15(10):1476-1480; doi:10.1093/annonc/mdh389
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tchirkov, A.
Right arrow Articles by Travade, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tchirkov, A.
Right arrow Articles by Travade, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Original Article

hTERT expression and prognosis in B-chronic lymphocytic leukemia

A. Tchirkov1,2,*, C. Chaleteix1, C. Magnac3, Y. Vasconcelos3,4, F. Davi5, A. Michel5, F. Kwiatkowski6, O. Tournilhac1, G. Dighiero3 and P. Travade1

1 Service d'Hématologie Clinique, CHU, Clermont-Ferrand; 2 Departement de Radiothérapie and 6 Service Statistiques et Communications Médicales, Centre Jean Perrin, Clermont-Ferrand; 3 Unité d'Immuno-Hématologie et d'Immunopathologie, Institut Pasteur, Paris; 5 Département d'Hématologie, Hôpital Pitié-Salpêtrière, Paris, France; 4 Division of Hematology, Universidade Federal de São Paulo, Sao Paulo, Brazil

* Correspondence to: Dr A. Tchirkov, Département de Radiothérapie, Centre Jean Perrin, 58, rue Montalembert, B.P. 392, 63011 Clermont-Ferrand Cedex 1, France. Tel: +33-4-73-27-83-75; Fax: +33-4-73-27-81-25; Email: andrei.tchirkov{at}cjp.fr

Background: In B-chronic lymphocytic leukemia (B-CLL), there is a need for molecular markers to predict the evolution of this heterogeneous disease in individual patients. The level of expression of the human telomerase reverse transcriptase (hTERT) gene has been associated with disease aggressiveness in human cancers. The purpose of the present study was to examine the prognostic significance of hTERT expression in B-CLL.

Patients and methods: We used real-time reverse transcription-PCR to quantitate the amount of hTERT transcripts in mononuclear blood cells from 90 B-CLL patients. In addition, samples were analyzed for somatic mutations in the immunoglobulin V (IgV) genes.

Results: The expression of hTERT gene was detected in 59% of patients. The level of expression increased with advancing B-CLL stage (P=0.0064). Patients expressing hTERT showed significantly shorter survival than hTERT-negative patients (P=0.000034), irrespective of the disease stage. On average, the level hTERT mRNA expression was seven-fold higher in the poor-prognosis B-CLL group with unmutated IgV than in the Ig-mutated group (P<10–7). The level of hTERT expression discriminated the Ig-unmutated from Ig-mutated B-CLL in 89% of cases.

Conclusion: Our data indicate that hTERT expression in B-CLL may serve as a molecular prognostic marker.

Key words: B-CLL, hTERT, prognosis, real-time reverse transcription-PCR


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
A. W. Hauswirth and U. Jager
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
Haematologica, January 1, 2008; 93(1): 14 - 19.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc., May 1, 2007; 18(5): 931 - 939.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Grabowski, M. Hultdin, K. Karlsson, G. Tobin, A. Aleskog, U. Thunberg, A. Laurell, C. Sundstrom, R. Rosenquist, and G. Roos
Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status
Blood, June 15, 2005; 105(12): 4807 - 4812.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.